Sort   by:  
 Page size 
ProteomicsCorrection of cognitive deficits in mouse models of Down syndrome by pharmacological inhibitor of DYRK1A
Down Syndrome (DS) results from the trisomy of human chromosome 21 (HSA21). It is still the most frequent intellectual disability, affecting 1 newborn per 700 births. Among candidate genes explaining intellectual disabilities seen in DS patients, the dual specificity tyrosine-phosphorylation regulat...
ORGANISM(S): Mus musculus (Mouse) 
2018-10-17 | PXD008419 | Pride
Kinase inhibitor Down syndrome Synapsin Dyrk1a Leucettine 
UnknownDYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets.
Not available
S-EPMC10191338 | biostudies-literature
UnknownDevelopment of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity.
Not available
S-EPMC8468039 | biostudies-literature
UnknownBiological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A.
Not available
S-EPMC6958357 | biostudies-literature
UnknownCorrection of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Not available
S-EPMC6176987 | biostudies-literature
Sort   by:  
 Page size